Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Newsletter out

<< Previous

Bullboard Posts

Next >>

Comment by 2b7f6fabon Apr 27, 2021 8:33am

170 Views

Post# 33073014

RE:RE:RE:Newsletter out

I would also add the 2 of 3 complete response from Ph1b. Those patients received the full dose and correct bladder/light calculations. So that give us 4/6 showing complete response with 3 pending. 67% complete response and patient 4 from Ph1b shouldn't even be considered in the %. Hence 4/5 or 80% CR with 3 pending. Very possible we're looking at 7/8 CR 3 months from now.

We should of been at this point a year ago if it wasn't for the mistreatments earlier in the trial.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments